NCT06779253View on ClinicalTrials.gov

A Study to Investigate The Effect of Pimicotinib on The Pharmacokinetics of Metformin, Fexofenadine and Rosuvastatin In Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

March 14, 2025

Primary Completion Date

April 4, 2025

Study Completion Date

May 22, 2025

Conditions
Healthy Subjects
Interventions
DRUG

pimicotinib capsules

the effect of multiple oral doses of pimicotinib (50 mg QD) on the pharmacokinetics of fexofenadine (P-gp sensitive substrate), rosuvastatin (BCRP sensitive substrate) and metformin (MATE1 sensitive substrate). Fexofenadine and rosuvastatin will be administered together as a cocktail, and metformin will be given via staggered dosing from the cocktail drugs administration

Trial Locations (1)

250014

The First Affiliated Hospital Shandong First Medical University (Shandong Provincial Qianfoshan Hospital), Jinan

Sponsors
All Listed Sponsors
lead

Abbisko Therapeutics Co, Ltd

INDUSTRY

NCT06779253 - A Study to Investigate The Effect of Pimicotinib on The Pharmacokinetics of Metformin, Fexofenadine and Rosuvastatin In Healthy Subjects | Biotech Hunter | Biotech Hunter